Breuer Kristine, Braeutigam Matthias, Kapp Alexander, Werfel Thomas
Department of Dermatology and Allergology, Hannover Medical University, Germany.
Dermatology. 2004;209(4):314-20. doi: 10.1159/000080855.
In the published studies on the efficacy of the topical immunomodulator pimecrolimus, different eczema scores were used, and the impact on morphological key signs of eczema was not analysed.
To compare the influence of pimecrolimus cream 1% on different standard eczema scores in infants with atopic dermatitis and to analyse the impact of treatment on the individual morphological key signs of eczema.
Pimecrolimus cream 1% (n = 129) or double-blind vehicle control (n = 66) was administered for 4 weeks. The Eczema Area and Severity Index (EASI), Investigators' Global Assessment (IGA) and Scoring Atopic Dermatitis Index (SCORAD) were determined and were correlated with each other.
Following treatment with pimecrolimus, the EASI, IGA and SCORAD were significantly reduced on day 29 as compared with the vehicle group (p < 0.001, p < 0.001, p = 0.002, respectively). There was a close correlation between EASI, IGA and SCORAD. The single parameters of the EASI were already significantly decreased by day 4 in the pimecrolimus group as compared to vehicle (each p < 0.001).
Treatment with pimecrolimus 1% cream leads to a rapid improvement of all morphological signs of eczema. The close correlation of different scores was shown for the first time.
在已发表的关于外用免疫调节剂吡美莫司疗效的研究中，使用了不同的湿疹评分，且未分析其对湿疹形态学关键体征的影响。
比较1%吡美莫司乳膏对特应性皮炎婴儿不同标准湿疹评分的影响，并分析治疗对湿疹个体形态学关键体征的影响。
给予1%吡美莫司乳膏（n = 129）或双盲赋形剂对照（n = 66），持续4周。测定湿疹面积及严重程度指数（EASI）、研究者整体评估（IGA）和特应性皮炎评分指数（SCORAD），并分析它们之间的相关性。
与赋形剂组相比，吡美莫司治疗后第29天，EASI、IGA和SCORAD均显著降低（分别为p < 0.001、p < 0.001、p = 0.002）。EASI、IGA和SCORAD之间密切相关。与赋形剂组相比，吡美莫司组在第4天时EASI的单个参数已显著降低（各p < 0.001）。
1%吡美莫司乳膏治疗可使湿疹的所有形态学体征迅速改善。首次显示了不同评分之间的密切相关性。
